Collectively, these findings serve to define the pathogenesis of CNS inflammation–induced myelin damage and support a potential therapeutic strategy of using Kv1.3 blocker to treat MS and white matter damage in other neurological disorders. The gene discussed is KCNA3; the disease is myeloid sarcoma.